Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...

Rare cranial disorders: Towards a non-invasive therapy using gene silencing delivered by nanoparticles and 3D printing

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...
Le Lézard

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com

Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering. The market size of CGT ...
Drug Target Review

ELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge

Join the ELRIG conference to hear from experts on cell and gene therapy. Discover advancements shaping the future of medicine.

Gene Therapy Market Outlook 2026-2031, Featuring Profiles of REGENXBIO, Oxford Biomedica, Voyager Therapeutics and More

Key trends include strategic CDMO partnerships and a shift to in vivo administration, enhancing accessibility and innovation ...

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific ...